Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.

This T reg cell depletion has a close correlation with complete CML remission at the molecular level, and is therefore a highly significant biomarker of molecular remission as revealed by receiver operating characteristic (ROC) curve analysis ( Fig. 1 C ).

also in 132,142 other papers